Arlinda Lee
Stock Analyst at Canaccord Genuity
(2.21)
# 2,712
Out of 4,876 analysts
46
Total ratings
43.48%
Success rate
7.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arlinda Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCTH Delcath Systems | Maintains: Buy | $18 → $21 | $13.57 | +54.75% | 3 | Sep 7, 2023 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $600 → $300 | $1.83 | +16,293.44% | 3 | Apr 5, 2022 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $375 → $90 | $25.76 | +249.38% | 5 | Mar 16, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $45 → $36 | $62.73 | -42.61% | 3 | Mar 7, 2022 | |
| CELC Celcuity | Initiates: Buy | $50 | $12.54 | +298.72% | 1 | Oct 8, 2021 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $151 → $160 | $47.49 | +236.91% | 3 | Aug 16, 2021 | |
| BCYC Bicycle Therapeutics | Maintains: Buy | $36 → $40 | $7.24 | +452.49% | 3 | Jul 15, 2021 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $92 → $105 | $36.52 | +187.51% | 12 | Oct 29, 2020 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $23 → $27 | $52.21 | -48.29% | 3 | May 19, 2020 | |
| BPMC Blueprint Medicines | Maintains: Buy | $115 → $100 | $128.11 | -21.94% | 5 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $2.35 | +2,027.66% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $270 | $4.33 | +6,135.57% | 3 | Nov 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $160 | $1.16 | +13,703.81% | 1 | Mar 29, 2018 |
Delcath Systems
Sep 7, 2023
Maintains: Buy
Price Target: $18 → $21
Current: $13.57
Upside: +54.75%
X4 Pharmaceuticals
Apr 5, 2022
Maintains: Buy
Price Target: $600 → $300
Current: $1.83
Upside: +16,293.44%
Nektar Therapeutics
Mar 16, 2022
Maintains: Buy
Price Target: $375 → $90
Current: $25.76
Upside: +249.38%
Rhythm Pharmaceuticals
Mar 7, 2022
Maintains: Buy
Price Target: $45 → $36
Current: $62.73
Upside: -42.61%
Celcuity
Oct 8, 2021
Initiates: Buy
Price Target: $50
Current: $12.54
Upside: +298.72%
CRISPR Therapeutics AG
Aug 16, 2021
Maintains: Buy
Price Target: $151 → $160
Current: $47.49
Upside: +236.91%
Bicycle Therapeutics
Jul 15, 2021
Maintains: Buy
Price Target: $36 → $40
Current: $7.24
Upside: +452.49%
Ultragenyx Pharmaceutical
Oct 29, 2020
Maintains: Buy
Price Target: $92 → $105
Current: $36.52
Upside: +187.51%
Halozyme Therapeutics
May 19, 2020
Maintains: Buy
Price Target: $23 → $27
Current: $52.21
Upside: -48.29%
Blueprint Medicines
Apr 30, 2020
Maintains: Buy
Price Target: $115 → $100
Current: $128.11
Upside: -21.94%
Feb 24, 2020
Initiates: Buy
Price Target: $50
Current: $2.35
Upside: +2,027.66%
Nov 5, 2019
Maintains: Buy
Price Target: $225 → $270
Current: $4.33
Upside: +6,135.57%
Mar 29, 2018
Maintains: Buy
Price Target: $300 → $160
Current: $1.16
Upside: +13,703.81%